[High dose therapy with autologous stem cell support in malignant disorders. Excerpt from the statement by the advisory group of the State Health Services].
New biomedical knowledge may improve the diagnostic procedures and treatment provided by the Health Services, but at additional cost. In a social democratic health care system, the hospital budgets have no room for expensive, new procedures or treatments, unless these are funded through extra allocation from the central authorities. High dose therapy with autologous stem cell support in malignant disorders is an example of a new and promising, but rather expensive treatment, but its role in cancer therapy has yet to be established. The indications for testing high dose therapy with autologous stem cell support in various malignancies are discussed, with emphasis on the principles for deciding which categories of disease should have priority. The authors suggest some malignant disorders for which high dose therapy with stem cell support should be explored versus conventional treatment in randomised prospective trials.
Holte
H
H
Onkologisk avdeling, Det Norske Radiumhospital, Oslo.
Kvaløy
S O
SO
Engan
T
T
Evensen
S A
SA
Mella
O
O
Tangen
J M
JM
Wesenberg
F
F
Wist
E A
EA
D003362:Cost-Benefit Analysis; D006291:Health Policy; D006292:Health Priorities; D018380:Hematopoietic Stem Cell Transplantation / Q000191:economics; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy / Q000628:therapy*; D009664:Norway; D011879:Radiotherapy Dosage; D014182:Transplantation, Autologous